Heidelberg Pharma Reports Promising Clinical Data for Multiple Myeloma Treatment HDP-101
Heidelberg Pharma will present new clinical data showing objective responses and anti-tumor activity in multiple myeloma patients treated with its lead antibody-drug conjugate candidate HDP-101, highlighting its potential to address significant unmet medical needs in relapsed or refractory cases.
Heidelberg Pharma AG will present new clinical data from its ongoing Phase I/IIa study evaluating HDP-101, the company's lead Amanitin-based antibody-drug conjugate candidate for relapsed or refractory multiple myeloma. The data, to be presented at the 16th Annual World ADC Congress in San Diego, demonstrates objective responses and promising anti-tumor activity observed across several patient cohorts in the trial.
The clinical results reinforce the therapeutic potential and safety profile of HDP-101 in treating multiple myeloma, a bone marrow cancer with high unmet medical need. Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma, will present an update from patient cohort 8 including efficacy data from the open-label, multicenter study. The presentation titled "From Bench to Breakthrough: The Evolution of Amanitin ADCs - Insights from HDP-101 Phase I/II & the Future of Payload Differentiation" will take place on Wednesday, November 5, 2025, at 5:00 pm PST at the Town & Country San Diego venue.
Following the congress, Heidelberg Pharma will host an R&D webinar on November 11, 2025, at 05:00 pm CET for investors, analysts, and media. The webinar will feature presentations by the Heidelberg Pharma management team alongside Key Opinion Leader Professor Marc-Steffen Raab, Head of the Myeloma Center at the University Hospital Heidelberg and clinical investigator of the study. Participants can register for the webinar using the link https://us06web.zoom.us/webinar/register/WN_AG_mESPaT-aSsm8_O2Dll.
HDP-101 represents a novel approach in cancer treatment as Heidelberg Pharma is the first company to use the compound Amanitin from the green death cap mushroom in cancer therapy. The biological mechanism of action of this toxin represents a new therapeutic modality used in the company's ATAC technology platform. The Phase I portion of the ongoing study is a dose-escalation trial designed to determine the optimal and safe dose level of HDP-101 in preparation for subsequent Phase II clinical evaluation.
Multiple myeloma remains a challenging cancer to treat, particularly in patients who have relapsed or become refractory to existing therapies. The promising data from HDP-101's clinical development suggests potential for a new treatment option that could address this significant medical need. A recording of the R&D webinar will be accessible via the press and investor section of the company website at www.heidelberg-pharma.com after the event.